HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]
HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]
HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy […]
HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics […]
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Stock analysts at Leerink Partnrs boosted their Q2 2024 earnings estimates for Cartesian Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.95) per share for the quarter, up from their prior […]